PROKIDNEY CORP.

ProKidney Corp. (Nasdaq: PROK) is a clinical-stage biopharmaceutical company focused on developing cell-based therapeutics for chronic kidney disease, a condition affecting tens of millions of patients in the United States alone. The company entered the public markets in 2022 through a de-SPAC business combination, and filed an S-1/A amendment with the Securities and Exchange Commission on August 26, 2022, under accession number 0001193125-22-231275, as part of the registration process for its combined-company securities. PROK operates in the healthcare and biotechnology sector, with its lead program targeting the preservation and restoration of kidney function. The company's public listing reflects a broader wave of life-sciences de-SPAC transactions that characterized the 2021–2022 market cycle. For complete filing history, deal terms, and real-time SPAC data on PROK and hundreds of other transactions, sign up for full access at SpacDesk.